Melanoma & Skin Cancer | Specialty

The OncLive Melanoma & Skin Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of skin cancers, including melanoma, basal cell carcinoma, and more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in melanoma and other skin cancers.

Cobolimab Plus Dostarlimab Achieves Clinical Responses in Advanced Melanoma

June 24th 2022

Treatment with the combination of cobolimab and dostarlimab led to an overall objective response rate and immune-related ORR of 42.9% consisting of all partial responses in patients with advanced or metastatic melanoma.

Treatment Options for Locally Advanced Basal Cell Carcinoma

June 23rd 2022

Experts review the currently available treatment options for locally advanced basal cell carcinoma.

Referring Patients with Basal Cell Carcinoma to Medical Oncology

June 23rd 2022

Dr. Shahab Babakoohi explains when to refer a patient with basal cell carcinoma from a dermatology practice to a medical oncologist.

T-VEC Plus Pembrolizumab Generates Promising Responses, Safety in PD-1–Refractory Advanced Melanoma

June 20th 2022

Adding talimogene laherparepvec to pembrolizumab led to encouraging responses with a manageable safety profile in patients with advanced melanoma who progressed on prior anti–PD-1 therapy, most notably in the adjuvant setting, according to findings from the phase 2 MASTERKEY-115 trial.

Cosibelimab Continues to Show Promise in Locally Advanced Cutaneous Squamous Cell Carcinoma

June 16th 2022

The PD-L1 antibody cosibelimab was found to elicit an encouraging objective response rate in patients with locally advanced cutaneous squamous cell carcinoma who were not eligible to undergo curative surgery or radiation.

Quavonlimab/Pembrolizumab Combo Shows Modest Antitumor Activity in Advanced Melanoma

June 16th 2022

The combination of quavonlimab and pembrolizumab was found to be generally well tolerated and to have modest antitumor activity in patients with advanced melanoma that progressed on a PD-1/PD-L1 inhibitor, according to data from a phase 1/2 trial (NCT03179436).

Clinical Scenario 1: A 74-Year-Old Man with Locally Advanced Infiltrative Basal Cell Carcinoma

June 15th 2022

Jennifer Atlas, MD, presents the clinical scenario of a man with locally advanced basal cell carcinoma.

Gibney Breaks Down the Evolving Treatment Landscape of Melanoma

June 15th 2022

Geoffrey T. Gibney, MD, discusses current treatment options for patients with melanoma, clinical trials that have explored different agents and combinations, and developing treatment options in uveal melanoma.

Overview of Basal Cell Carcinoma

June 15th 2022

Shahab Babakoohi, MD, describes the incidence patterns, options for testing and diagnosis, and risk stratification for basal cell carcinoma.

Nivolumab Plus Relatlimab Demonstrates Sustained PFS Benefit in Advanced Melanoma

June 6th 2022

Fixed-dose nivolumab plus relatlimab elicited continued progression-free survival benefit vs nivolumab alone in patients with treatment-naïve, unresectable or metastatic melanoma, according to updated results from the phase 2/3 RELATIVITY-047 trial.

Adjuvant Pembrolizumab Results in Significant DMFS Improvement Over Placebo in Stage II Melanoma

June 5th 2022

Adjuvant pembrolizumab was found to result in a significant improvement in distant metastasis-free survival compared with placebo, with a continued reduction in risk of recurrence and an acceptable safety profile, in patients with resected stage IIB or stage IIC melanoma.

FDA Lifts Partial Clinical Hold on NEON-2 Trial Evaluating Davoceticept Plus Pembrolizumab in Advanced Malignancies

May 24th 2022

The FDA has lifted a partial clinical hold on the phase 1 NEON-2 trial investigating the use of davoceticept in combination with pembrolizumab in adult patients with advanced solid tumors or lymphoma.

Tilsotolimod Demonstrates Encouraging Activity, Safety in Early-Stage Melanoma

May 23rd 2022

The synthetic Toll-like receptor 9 agonist tilsotolimod reduced the sentinel lymph node biopsy positivity rate vs placebo in patients with localized, excised melanoma.

Molecular Approaches May Increase Responsiveness to Immunotherapy for Patients With Metastatic Melanoma

May 23rd 2022

The recent development of therapeutics which stimulate immune response to tumor cells has revolutionized the treatment landscape for cutaneous melanoma.

Pembrolizumab Moves Toward EU Approval for Resected Stage IIB/IIC Melanoma

May 20th 2022

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of pembrolizumab for use as adjuvant therapy in adult and adolescent patients aged 12 years and older with stage IIB or IIC melanoma following complete resection.

TLR9 Agonist Vidutolimod Shows Promise in Combination With Pembrolizumab in PD-1–Refractory Melanoma

May 19th 2022

The combination of intratumoral vidutolimod and intravenous pembrolizumab demonstrated promising clinical activity in patients with PD-1 refractory melanoma.

Closing Remarks on the Treatment of Patients With Metastatic Melanoma

May 17th 2022

Experts share closing remarks and provide advice for clinicians treating patients with metastatic melanoma.

Second-line Treatment Strategies for BRAF-mutant Metastatic Melanoma: Additional Patient Scenarios

May 17th 2022

Dr Michael Atkins and Dr Evan Lipson discuss additional second- and third-line treatment options.

Second-line Treatment Strategies for BRAF-mutant Metastatic Melanoma: Patient Profile Revisited

May 17th 2022

Dr Michael Atkins and Dr Evan Lipson revisit the first patient profile to discuss second- and third-line treatment options for patients with metastatic melanoma.

Sotigalimab Plus Nivolumab Shows Encouraging Activity in Anti–PD-1 Refractory Melanoma

May 13th 2022

The combination of sotigalimab and nivolumab elicited durable responses with a reasonable safety profile in patients with melanoma who were refractory to anti–PD-1 therapy, according to data from a phase 2 trial.